133343-34-7

133343-34-7 structure

Name: Lactacystin
Chemical Name: lactacystin
CAS Number: 133343-34-7
Molecular Formula: C₁₅H₂₄N₂O₇S
Molecular Weight: 376.425
Catalog: Biochemical Protein research
Create Date: 2018-06-26 18:13:05
Modify Date: 2024-01-02 13:00:20
Lactacystin, an antibiotic Streptomyces spp. metabolite, is a potent and selective proteasome inhibitor with an IC50 of 4.8 μM for 20S proteasome. Lactacystin also inhibits the lysosomal enzyme cathepsin A[1]. Lactacystin inhibits cell growth and induces neurite outgrowth[2].

Name	lactacystin
Synonyms	L-Cysteine, N-acetyl-S-[[(3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl]carbonyl]- (+)-Lactacystin MFCD01076525 N-Acetyl-S-({(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidin-2-yl}carbonyl)-L-cysteine L-cysteine, S-[[(2R,3S,4R)-3,4-dihydro-3,5-dihydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-2H-pyrrol-2-yl]carbonyl]-N-(1-hydroxyethylidene)-, (E)- L-Cysteine, N-acetyl-S-[[(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl]carbonyl]- LACTACYSTIN N-Acetyl-S-({(3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl}carbonyl)-L-cysteine N-Acetyl-S-({(2R,3S,4R)-3-hydroxy-2-[(1S)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinyl}carbonyl)-L-cysteine

Description	Lactacystin, an antibiotic Streptomyces spp. metabolite, is a potent and selective proteasome inhibitor with an IC50 of 4.8 μM for 20S proteasome. Lactacystin also inhibits the lysosomal enzyme cathepsin A[1]. Lactacystin inhibits cell growth and induces neurite outgrowth[2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Proteasome Research Areas >> Neurological Disease
Target	IC50: 4.8 μM (proteasome)[1]
In Vivo	Lactacystin (microinjection; 2 µg) induces a Parkinson’s disease-like motor phenotype 5-7 days after injection in young and adult mice[2]. Animal Model: Male C57Bl/6RccHsd mice with 8-9 weeks (young) and 12-14 months (adult) old[2] Dosage: 2 µg Administration: Microinjection Result: Induced a Parkinson’s disease-like motor phenotype 5-7 days after injection in young and adult mice.
References	[1]. Csizmadia V, et al. Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasomesystem in vitro. Vet Pathol. 2010 Mar;47(2):358-67. [2]. Savolainen MH, et al. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activationand shows various phenotypes of Parkinson's disease in young and adult mouse. Exp Brain Res. 2017 Jul;235(7):2189-2202.

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR	NONH for all modes of transport
WGK Germany	3